COVID-19 and the central nervous system

Alomari, Safwan; Abou-Mrad, Zaki; Bydon, Ali

doi:10.1016/j.clineuro.2020.106116

Cited by 57 publications

(63 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…um-PEA treatment may be able to modulate the mechanisms linked to PPARα and TLRs that are involved in SARS-CoV-2 infection [ 58 ]. In addition to the actions described above, um-PEA is also able to reduce oxidative stress and improve endothelial damage, the intestinal barrier integrity, and brain function [ 59 , 60 , 61 , 62 , 63 ].…”

Section: Ultramicronized-pea and Its Mechanisms Of Actionmentioning

confidence: 99%

Ultramicronized Palmitoylethanolamide (um-PEA): A New Possible Adjuvant Treatment in COVID-19 patients

et al. 2021

View full text Add to dashboard Cite

The Coronavirus Disease-19 (COVID-19) pandemic has caused more than 100,000,000 cases of coronavirus infection in the world in just a year, of which there were 2 million deaths. Its clinical picture is characterized by pulmonary involvement that culminates, in the most severe cases, in acute respiratory distress syndrome (ARDS). However, COVID-19 affects other organs and systems, including cardiovascular, urinary, gastrointestinal, and nervous systems. Currently, unique-drug therapy is not supported by international guidelines. In this context, it is important to resort to adjuvant therapies in combination with traditional pharmacological treatments. Among natural bioactive compounds, palmitoylethanolamide (PEA) seems to have potentially beneficial effects. In fact, the Food and Drug Administration (FDA) authorized an ongoing clinical trial with ultramicronized (um)-PEA as an add-on therapy in the treatment of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection. In support of this hypothesis, in vitro and in vivo studies have highlighted the immunomodulatory, anti-inflammatory, neuroprotective and pain-relieving effects of PEA, especially in its um form. The purpose of this review is to highlight the potential use of um-PEA as an adjuvant treatment in SARS-CoV-2 infection.

show abstract

Section: Ultramicronized-pea and Its Mechanisms Of Actionmentioning

confidence: 99%

Ultramicronized Palmitoylethanolamide (um-PEA): A New Possible Adjuvant Treatment in COVID-19 patients

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The novel coronavirus disease 2019 (COVID-19) is a global pandemic with international concern [ 1 ]. SAH is a devastating disease [ 2 ], which accounts for approximately 5–10 % of strokes [ 2 ] Several case report about the SAH and COVID-19 infection have been reported [ [3] , [4] , [5] , [6] ], but three reviews about the interaction between COVID-19 and the central nervous system have been recently published, but the occurrence of SAH in patients with Covid-19 infection has not been mentioned in these reviews [ [7] , [8] , [9] ]. There is limited knowledge on the SAH following COVID-19 at present.…”

Section: Introductionmentioning

confidence: 99%

COVID-19 infection produces subarachnoid hemorrhage; acting now to understand its cause: A short communication

Batçık

Kanat

Cankay

et al. 2021

Clinical Neurology and Neurosurgery

View full text Add to dashboard Cite

“…Severe hypoxemia, viremia, and brain edema can result in toxic encephalopathy in COVID-19 patients. 5 Acute necrotizing hemorrhagic encephalopathy (ANE)…”

Section: Infectious Toxic Encephalopathymentioning

confidence: 99%

“…Also, there are reports of the T2-FLAIR symmetrical hyperintensity with restricted diffusion in deep with mater in six patients. 5…”

Section: Leukoencephalopathymentioning

confidence: 99%

SARS coronavirus 2 and central nervous system manifestations: causation, relation, or coexistence? a case series study and literature review

Daneshi

Taheri

Fattahi

2020

British Journal of Neurosurgery

View full text Add to dashboard Cite

Introduction: Recently, weeks after the COVID-19 prevalence, there were reports of brain involvement and neurologic presentations in the COVID-19. Case presentation: We present five cases of COVID-19 and cerebrovascular events. A 34-year-old woman with IVH and ischemic stroke. A 60-year-old man with multiple small hemorrhagic foci and mild IVH in the occipital horn. A 63-year-old woman with large left parietooccipital intracerebral hemorrhage (ICH) and IVH. A 56-year-old man with left hemispheric and midbrain ICH, lateral ventricular IVH, and hydrocephalus. A 85-year-old woman with right parietal hemorrhagic infarct. The coagulation profile was normal in all of them. The chest CT scan showed the typical ground-glass appearance of COVID-19. Conclusions: Recently, there were reports of brain involvement and neurologic presentations in the COVID-19. These reports and the present study necessitate the aimed and designed studies with emphasis on neurologic presentations in COVID-19 patients to illustrate the exact effects of coronavirus-2 on the central nervous system.

show abstract

COVID-19 and the central nervous system

Cited by 57 publications

References 77 publications

Ultramicronized Palmitoylethanolamide (um-PEA): A New Possible Adjuvant Treatment in COVID-19 patients

Ultramicronized Palmitoylethanolamide (um-PEA): A New Possible Adjuvant Treatment in COVID-19 patients

COVID-19 infection produces subarachnoid hemorrhage; acting now to understand its cause: A short communication

SARS coronavirus 2 and central nervous system manifestations: causation, relation, or coexistence? a case series study and literature review

Contact Info

Product

Resources

About